Join to access to all OVN content. Join for Free
Best Practices and Creative Ways to Gain KOL Access During COVID-19
Provide 5 SEO Keywords separated by commas

Best Practices and Creative Ways to Gain KOL Access During COVID-19


Share This Article


Summary

In this episode, Tom Caravela speaks with Jason Demuth about his journey from retail pharmacy to the pharmaceutical industry. Jason shares his experiences engaging Key Opinion Leaders (KOLs) during COVID, emphasizing the strategic use of social media and email communication. The discussion explores the future of KOL access and offers strategies for aspiring MSLs. Jason compares roles in big pharma versus small pharma and highlights the importance of networking and recruiters in advancing MSL careers. The episode concludes with Jason's final thoughts and advice, alongside a call for listener engagement.

My guest today is Jason Demuth, Director, Medical Science Liaison at Strongbridge Bio shares creative ways to reach and access KOLs during COVID-19. 

In this episode we discuss:

  • Jason’s background
  • His journey and getting his first MSL role
  • Creative ideas and ways to access KOLs
  • His perspective on LinkedIn and Facebook for KOL engagement
  • Email interaction with KOLs
  • What is the future going to look like in terms of access in Jason’s perspective
  • His advice for new MSLs or those breaking into the role
  • Jason’s  advice for MSLs and/or MSL Leaders as we look to the future

Click for Source
Provide 5 SEO Keywords separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN